(Reuters)—U.S. drugstore chain operator CVS Health Corp said on Sunday it had agreed to acquire U.S. health insurer Aetna Inc. for $69 billion, seeking to tackle soaring healthcare spending through lower-cost medical services in pharmacies. This year’s largest corporate acquisition will combine one of the nation’s largest pharmacy benefits managers (PBMs) and pharmacy operators with…
Search results for: drug prices
Sen. Lisa Murkowski Addresses Rheumatologists During ACR/ARHP Annual Meeting, Tax Reform & More
Greetings, advocates! This month’s Washington update covers how Congress’s tax proposals affect rheumatology, the ACR’s plan to fight Medicare’s adjustments to Part B drug costs in MIPS, the good news of Medicare’s new individualized biosimilar reimbursement, advances in the rheumatology-specific Alternative Payment Model and developments in Congress’s awareness about the perilous pharmacy benefit manager system….
Biosimilars Great Debate: To Switch or Not?
SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…
Trump to Tap Ex-Pharma Executive Azar as U.S. Health Secretary
WASHINGTON (Reuters)—President Donald Trump on Monday said he will nominate former pharmaceutical executive and industry lobbyist Alex Azar to serve as U.S. Health and Human Services secretary, saying Azar would push to lower the price of medicines. If confirmed, Azar also would take the lead in implementing Trump’s campaign promise to dismantle the Affordable Care…
Ex-Pharma Exec Azar Is Top Choice to Run U.S. Health Agency
WASHINGTON (Reuters)—Alex Azar, a former pharmaceutical company executive, is U.S. President Donald Trump’s top pick to run the Department of Health and Human Services, two sources with knowledge of the confidential process said on condition of anonymity on Wednesday. Azar served at Eli Lilly for a decade, including five years as president of its U.S….
Health Insurer Anthem Takes Pharmacy Business in House, Taps CVS to Help
(Reuters)—Health insurer Anthem Inc will start managing its billions of dollars of patient prescriptions itself in 2020, it said on Wednesday, ending a deal with Express Scripts Holding that had deteriorated into lawsuits over terms. Anthem, which sued the pharmacy benefit manager last year over claims of being overcharged by $3 billion annually, said it…
Pfizer Files Suit Against J and J over Remicade Contracts
(Reuters)—Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson and Johnson, saying its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer’s new biosimilar. Pfizer said in the suit that Johnson and Johnson is offering discounts on its Remicade treatment in exchange for essentially excluding…
ATAP Holds Inaugural In-Person Meeting
The ACR recently announced the launch of the Alliance for Transparent & Affordable Prescriptions (ATAP), a coalition of provider and patient groups concerned about the role pharmacy benefit managers (PBMs) play in driving up drug costs. The inaugural ATAP in-person meeting wrapped up on July 19 in Washington, D.C. The Alliance currently consists of the…
Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment
While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy. “It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of…
Alliance Working to Rein in Power of PBMs
A coalition of patient and provider groups, including the ACR, is raising awareness about the effect of pharmacy benefit managers (PBMs) on patient care and the cost of prescription drugs. The Alliance for Transparent and Affordable Prescriptions, or ATAP, argues that too few restrictions have been placed on PBM transparency, and requirements for PBMs to…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 25
- Next Page »